Squamous Cell Carcinoma of the Head and NeckPhase 3NCT05751512
A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN
A Phase 3 study testing MRG003, Cetuximab injection and Methotrexate Injection in people with Squamous Cell Carcinoma of the Head and Neck, run by Lepu Biopharma Co., Ltd. at 1 site in China.
Trial summary
The objective of this study is to compare the efficacy and safety of MRG003 versus cetuximab/methotrexate as second/third line of therapy in patients with RM-SCCHN who have previously failed PD-1 (L1) inhibitors and platinum-based therapy. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Squamous Cell Carcinoma of the Head and Neck
- What is being tested?
- MRG003, Cetuximab injection and Methotrexate Injection
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 180 participants
- Where
- 1 siteChina
- Study dates
- 4 Apr 2023to Dec 2027
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 1. Understands and provides written informed consent and willing to follow the requirements specified in protocol.
- 2. Age: ≥18 years and ≤75 years. 3. Life expectancy: ≥3 months. 4. Must have histologically or cytologically confirmed recurrent or metastatic squamous cell carcinoma of the head and neck (including oral cavity, oropharynx, hypopharynx, larynx) who had previously failed PD-1 (L1) inhibitors and platinum-based therapy (in combination or sequential). Prior therapies should be no more than 2 lines.
- Note: If disease progression occurred during neoadjuvant/adjuvant treatment or concurrent radiotherapy, or within 6 months after treatment discontinuation, the anti-tumor therapies (including platinum-based chemotherapy, anti-EGFR monoclonal antibody, PD-1 (L1) inhibitors, etc.) during neoadjuvant/adjuvant treatment or concurrent radiotherapy is counted as one line of prior treatment. Discontinuation or dose reduction of one drug, or change of platinum- or fluorouracil-based agents or PD-1 (L1) inhibitors without disease progression is considered as the same line of treatment.
- 5. Must have at least one measurable lesion per RECIST v1.1. Previously irradiated lesion cannot be considered as target unless there is documented progression three months after the last treatment of radiotherapy.
- 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (Appendix 1) with no deterioration within 2 weeks prior to enrollment.
- 7. Adequate bone marrow function, defined as meeting all of the following criteria and having no transfusion therapy within 3 weeks (21 days) or growth factors (G-CSF, EPO, etc.) support within 2 weeks (14 days) prior to dosing:
Show all 19Show fewer
- Hemoglobin (Hb) ≥ 9.0 g/dL (90 g/L)
- Absolute neutrophil count (ANC) ≥ 1,500/mcL (1.5 × 109/L)
- Total platelet count (PLT) ≥ 100,000/mcL (100 × 109/L) 8. Adequate hepatic function, defined as all of the following:
- Total bilirubin (TBIL) ≤ 1.5×ULN;
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5×ULN if no liver metastasis; ALT or AST ≤ 3.0×ULN in the presence of liver metastasis;
- Alkaline phosphatase (ALP) ≤ 1.5×ULN; ≤ 2×ULN in the presence of liver metastasis;
- Serum albumin ≥ 30 g/L 9. Coagulation: International Normalized Ratio (INR) or prothrombin time (PT), activated partial thromboplastin time (APTT) ≤ 1.5×ULN (unless patient is receiving anticoagulant therapy whose anticoagulant level should be within the therapeutic range). The laboratory parameters should be closely monitored by investigator if the patient is on anticoagulation therapy.
- 10. Adequate renal function, defined as Creatinine ≤ 1.5×ULN or creatinine clearance rate (Ccr) ≥ 50 mL/min if Creatinine > 1.5×ULN (Creatinine clearance is calculated using the modified Cockcroft-Gault equation. Creatinine clearance can be calculated as Ccr = [(140-age) × body weight (kg) × (0.85 for women only)]/(72 × serum creatinine) if no local guidelines are available (without significant electrolyte imbalance that is not easily corrected).
- 11. Baseline Left Ventricular Ejection Fraction (LVEF) ≥ 50% measured by multiple-gated acquisition (MUGA) or echocardiogram (ECHO).
- 12. A negative serum or urine pregnancy test within 7 days prior to the first dose of study treatment (females of childbearing potential). If urine pregnancy test is positive or cannot be confirmed as negative, a confirmatory serum pregnancy test is required.
- 13. Patients, both females and males, of reproductive potential must agree to use adequate contraception during study treatment and for 180 days after the last treatment.
- Females of childbearing potential (who are not surgically sterile or postmenopausal for < 1 year) who are willing to use adequate and reliable contraception such as avoidance of heterosexual activity, sterilization, oral contraceptives, injectable contraceptives, intrauterine devices, condoms, etc., during the study until 180 days after the last dose of study drug.
- Male patients who are willing to use latex condoms during any sexual contact with females of childbearing potential during treatment until 180 days after the last treatment, even if vasectomy has been successfully performed. Reservation of semen specimen prior to the first dose of study treatment is recommended for fertile males for potential future conception.
Who cannot join
- 1. Grade ≥2 peripheral neuropathy per CTCAE v5.0. 2. Is expected to require surgery or any other form of systemic or local anti-tumor therapy during the study, including maintenance therapy or radiotherapy (including palliative therapy, except for palliative therapy for non-target lesions) for SCCHN.
- 3. Received systemic chemotherapy within 3 weeks, small molecule targeted therapy within 2 weeks or 5 half-lives (whichever is longer), biological anti-tumor therapy, macromolecule targeted therapy or immunotherapy within 4 weeks before the first dose of study treatment, or major surgery (except for minor surgery within 2 weeks and fully recovered); radiotherapy (except radiotherapy for CNS, wash-out period ≥ 28 days is required) within 14 days before the first dose of study treatment.
- 4. Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Patients with brain metastases may participate provided they are treated and stable, and do not have the following:
- Progressive or new neurological deficits, seizures, evidence of increased intracranial pressure, vomiting, or headache;
- Evidence of enlarging brain metastases by MRI at least 4 weeks prior to the first dose and corticosteroids is required for at least 14 days prior to study drug treatment.
- 5. Residual toxicities (except alopecia, fatigue, and Grade 2 hypothyroidism) due to prior anti-tumor therapy (including immunotherapy, targeted therapy, chemotherapy or radiotherapy) or ≥ Grade 1 (CTCAE v5.0) clinically significant laboratory abnormality.
Show all 22Show fewer
- 6. Uncontrolled or poorly controlled cardiac dysfunction, including congestive heart failure (CHF) ≥ Grade 2 (CTCAE v5.0 or New York Heart Association classification), history of myocardial infarction, unstable angina pectoris, ventricular tachycardia or torsades de pointes, or cardiac rhythm loss requiring treatment within 6 months prior to enrollment, for example, QTcF > 450 ms in men, QTcF > 470 ms in women, in presence of complete left bundle branch block or third-degree atrioventricular block. QTcF = QT/ (RR^0.33).
- 7. Pulmonary embolism or deep venous thrombosis (except for thrombosis caused by infusion port or PICC line) within 3 months prior to the first dose of study drug.
- 8. Known history of malignancy (except for patients with cutaneous basal cell carcinoma, superficial bladder carcinoma, cutaneous squamous cell carcinoma, carcinoma in situ, or papillary thyroid carcinoma who have undergone curative surgery) unless the patient has received potentially curative therapy and has not had disease recurrence within 5 years prior to study treatment.
- Note: The 5-year recurrence-free time requirement does not apply to SCCHN patients enrolled in this study.
- 9. Any serious or uncontrolled systemic disease, including uncontrolled or poorly controlled hypertension (e.g., systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg), diabetes mellitus (glycosylated hemoglobin (HbA1c) > 8%), etc.
- 10. Patients with active bleeding, history of coagulopathy, or receiving coumarin anticoagulant therapy.
- 11. Known allergic reactions to any component or excipients of MRG003 (citric acid monohydrate, sodium citrate dihydrate, trehalose dihydrate, sodium chloride, and polysorbate 80) or known allergic reactions to other anti-EGFR agents (including investigational drug) or to other monoclonal antibodies ≥ Grade 3.
- 12. Known active hepatitis B or C. Active hepatitis B is defined as known positive HBsAg result and HBV DNA ≥ 500 IU/mL. Active hepatitis C is defined as known positive hepatitis C antibody result and known quantitative hepatitis C virus (HCV) RNA results greater than the lower limit of detection. Presence of other serious liver diseases, including chronic autoimmune hepatic disorders, primary biliary cirrhosis or sclerosing cholangitis, alcoholic liver disease, or nonalcoholic steatohepatitis (NASH).
- 13. Concurrent, serious, uncontrolled infection or known infection with human immunodeficiency virus (HIV) (HIV antibody positive), or diagnosis of acquired immunodeficiency syndrome (AIDS); or uncontrolled autoimmune disease; or previous allogeneic tissue/organ transplantation, stem cell or bone marrow transplantation, or previous solid organ transplantation.
- 14. Active bacterial, viral, fungal, rickettsial, or parasitic infection requiring systemic anti-infection therapy (unless treated and resolved prior to study treatment).
- 15. Received live-virus vaccines within 30 days prior to the first dose of study treatment. Seasonal influenza vaccines or approved COVID-19 vaccines that do not contain live virus are permitted if vaccinated more than 1 week before the first dose of study treatment.
- 16. History of interstitial pneumonia, severe chronic obstructive pulmonary disease with respiratory failure, severe pulmonary insufficiency, symptomatic bronchospasm, etc.
- 17. Patients who are receiving an immunologically based treatment for any reason, including chronic use of systemic steroids equivalent to > 10 mg/day of prednisone within 7 days prior to the first dose of study treatment or at any time during the study. Note: Use of inhaled or topical steroids or systemic corticosteroids equivalent to ≤ 10 mg/day prednisone is permitted, as is short-term use of corticosteroids at doses equivalent to > 10 mg/day prednisone (e.g., pre-medication prior to contrast).
- 18. Uncontrolled pleural, abdominal, pelvic effusion or pericardial effusion that requires ≥ 1 drainage per month.
- 19. Any patient with a positive pregnancy or is breast-feeding. Female and male patients who are not expected to use adequate contraception during treatment and for 180 days after the last dose of treatment.
- 20. Any other disease or clinically significant abnormality in laboratory parameters, or serious medical or psychiatric illnesses/conditions, substance abuse disorder including alcoholism, which in the judgment of the Investigator might compromise the safety of the patient, integrity of the study, interfere with the patient participation in the study, or confound or compromise the study objectives and their interpretability.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Shanghai East Hospital
Shanghai, Shanghai Municipality, 200123
Ye Guo, pattrickguo@gmail.com
About this study
Official title: A Randomized, Open-Label, Multicenter, Phase III Study to Evaluate MRG003 vs Cetuximab/Methotrexate as Second/Third Line of Treatment in Patient With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (RM-SCCHN)
The objective of this study is to compare the efficacy and safety of MRG003 versus cetuximab/methotrexate as second/third line of therapy in patients with RM-SCCHN who have previously failed PD-1 (L1) inhibitors and platinum-based therapy.
Read the detailed description
This is a randomized, open-label, multicenter Phase III study to compare the efficacy and safety of MRG003 versus cetuximab/methotrexate as second/third line of therapy in patients with RM-SCCHN who have previously failed PD-1 (L1) inhibitors and platinum-based therapy. Approximately 180 patients will be enrolled, randomized, and stratified according to the following: Eastern Cooperative Oncology Group Performance Status (ECOG PS, 0 vs 1) and prior treatment with anti-EGFR mAb (yes vs no). For patients in the control group, cetuximab will be selected as comparator if no prior treatment with anti-EGFR mAb; otherwise, methotrexate will be selected.
After signing the informed consent and screened per inclusion/exclusion criteria, eligible patients will be randomized at a ratio of 1 : 1 and treated with MRG003 (2.3 mg/kg, IV, d1, Q3W) or cetuximab (400 mg/m2 for the first week and 250 mg/m2 for subsequent weeks, QW) / methotrexate (40 mg/m2, IV, QW) until disease progression, death, intolerable toxicity, withdrawal of consent, initiation of a new anti-tumor therapy, or other reasons leading to treatment discontinuation as specified by protocol.
- Being tested
- MRG003, Cetuximab injection, Methotrexate Injection
- Keywords
- MRG003, Antibody Drug Conjugate (ADC), SCCHN
- Medical subject headings
- Squamous Cell Carcinoma of Head and Neck
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MRG003Drug
Administered intravenously
Cetuximab injectionDrug
Administered intravenously
Methotrexate InjectionDrug
Administered intravenously
| Study group | Role | What they receive |
|---|---|---|
| MRG003 | Experimental | MRG003 will be administrated via intravenous infusion at 2.3 mg/kg once on Day 1 of every 3 weeks (21-day cycle). Receives: Drug: MRG003 |
| cetuximab/ methotrexate | Active comparator | cetuximab (400 mg/m2 for the first week and 250 mg/m2 for subsequent weeks, QW) or methotrexate (40 mg/m2, IV, QW) Receives: Drug: Cetuximab injection; Drug: Methotrexate Injection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall Survival (OS)
OS is defined as the duration from the start of treatment to death of any cause.
Measured: Baseline to study completion (up to 24 months)
Secondary outcomes (8)
Progression Free Survival (PFS)
PFS is defined as the duration from the start of treatment to the onset of tumor progression or death of any cause.
Measured: Baseline to study completion (up to 24 months)
Objective Response Rate (ORR)
ORR is defined as the proportions of patients with a complete response (CR) and partial response (PR). ORR will be assessed by investigator according to RECIST v1.1.
Measured: Baseline to study completion (up to 24 months)
Disease Control Rate (DCR)
DCR is defined as the proportion of subjects achieving CR, PR, and SD after treatment.
Measured: Baseline to study completion (up to 24 months)
Duration of Response (DOR)
DOR is defined as the duration from the initial recording of objective disease response to the first onset of tumor progression, or death of any cause.
Measured: Baseline to study completion (up to 24 months)
Treatment Related Adverse Events (TRAE)
Any reaction, side effect, or untoward event that occurs during the course of the clinical trial is considered related to the study drug.
Measured: Baseline to 30 days after the last dose of study treatment
Adverse Events (AEs)
Any reaction, side effect, or untoward event that occurs during the course of the clinical trial whether or not the event is considered related to the study drug.
Measured: Baseline to 30 days after the last dose of study treatment
Serious Adverse Events (SAEs)
Adverse events that are difficult to deal with in clinical drug research
Measured: Baseline to 90 days after the last dose of study treatment
Quality of Life (QOL) scores
Quality of Life is a concept of comprehensive evaluation of the advantages and disadvantages of life. It mainly refers to the assessment of individual physiological, psychological and social functions, which is an important indicator of the effectiveness of medical and health care services.
Measured: Baseline to study completion (up to 24 months)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Mar 2023
- Study start4 Apr 2023
- Primary completionDec 2027 (estimated)
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Squamous Cell Carcinoma of the Head and NeckStudies of the same condition, open and under way.
- More trials run by Lepu Biopharma Co., Ltd.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 180 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Lepu Biopharma Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Ye Guo, PhD, Principal investigator, Shanghai East Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05751512
- Sponsor's protocol ID
- MRG003-010
- Status last verified
- Sep 2026
- First submitted
- 21 Feb 2023
- Last updated
- 4 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Open-Label, Multicenter, Phase III Study to Evaluate MRG003 vs Cetuximab/Methotrexate as Second/Third Line of Treatment in Patient With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (RM-SCCHN)
- ClinicalTrials.gov ID
- NCT05751512
- Acronym / sponsor ID
- MRG003-010
- Keywords
- MRG003, Antibody Drug Conjugate (ADC), SCCHN
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 180 participants (estimated)
- Lead sponsor
- Lepu Biopharma Co., Ltd.Industry (pharma, biotech, devices)
- Study start
- 4 Apr 2023 (actual)
- Primary completion
- Dec 2027 (estimated)
- Study completion
- Dec 2027 (estimated)
- First posted
- 2 Mar 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this study is to compare the efficacy and safety of MRG003 versus cetuximab/methotrexate as second/third line of therapy in patients with RM-SCCHN who have previously failed PD-1 (L1) inhibitors and platinum-based therapy.
Detailed description
This is a randomized, open-label, multicenter Phase III study to compare the efficacy and safety of MRG003 versus cetuximab/methotrexate as second/third line of therapy in patients with RM-SCCHN who have previously failed PD-1 (L1) inhibitors and platinum-based therapy. Approximately 180 patients will be enrolled, randomized, and stratified according to the following: Eastern Cooperative Oncology Group Performance Status (ECOG PS, 0 vs 1) and prior treatment with anti-EGFR mAb (yes vs no). For patients in the control group, cetuximab will be selected as comparator if no prior treatment with anti-EGFR mAb; otherwise, methotrexate will be selected.
After signing the informed consent and screened per inclusion/exclusion criteria, eligible patients will be randomized at a ratio of 1 : 1 and treated with MRG003 (2.3 mg/kg, IV, d1, Q3W) or cetuximab (400 mg/m2 for the first week and 250 mg/m2 for subsequent weeks, QW) / methotrexate (40 mg/m2, IV, QW) until disease progression, death, intolerable toxicity, withdrawal of consent, initiation of a new anti-tumor therapy, or other reasons leading to treatment discontinuation as specified by protocol.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| MRG003 | Experimental | Drug: MRG003MRG003 will be administrated via intravenous infusion at 2.3 mg/kg once on Day 1 of every 3 weeks (21-day cycle). |
| cetuximab/ methotrexate | Active comparator | Drug: Cetuximab injection, Drug: Methotrexate Injectioncetuximab (400 mg/m2 for the first week and 250 mg/m2 for subsequent weeks, QW) or methotrexate (40 mg/m2, IV, QW) |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (19 listed)
- 1. Understands and provides written informed consent and willing to follow the requirements specified in protocol.
- 2. Age: ≥18 years and ≤75 years. 3. Life expectancy: ≥3 months. 4. Must have histologically or cytologically confirmed recurrent or metastatic squamous cell carcinoma of the head and neck (including oral cavity, oropharynx, hypopharynx, larynx) who had previously failed PD-1 (L1) inhibitors and platinum-based therapy (in combination or sequential). Prior therapies should be no more than 2 lines.
- Note: If disease progression occurred during neoadjuvant/adjuvant treatment or concurrent radiotherapy, or within 6 months after treatment discontinuation, the anti-tumor therapies (including platinum-based chemotherapy, anti-EGFR monoclonal antibody, PD-1 (L1) inhibitors, etc.) during neoadjuvant/adjuvant treatment or concurrent radiotherapy is counted as one line of prior treatment. Discontinuation or dose reduction of one drug, or change of platinum- or fluorouracil-based agents or PD-1 (L1) inhibitors without disease progression is considered as the same line of treatment.
- 5. Must have at least one measurable lesion per RECIST v1.1. Previously irradiated lesion cannot be considered as target unless there is documented progression three months after the last treatment of radiotherapy.
- 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (Appendix 1) with no deterioration within 2 weeks prior to enrollment.
Key exclusion criteria (22 listed)
- 3. Received systemic chemotherapy within 3 weeks, small molecule targeted therapy within 2 weeks or 5 half-lives (whichever is longer), biological anti-tumor therapy, macromolecule targeted therapy or immunotherapy within 4 weeks before the first dose of study treatment, or major surgery (except for minor surgery within 2 weeks and fully recovered); radiotherapy (except radiotherapy for CNS, wash-out period ≥ 28 days is required) within 14 days before the first dose of study treatment.
- 4. Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Patients with brain metastases may participate provided they are treated and stable, and do not have the following:
- 5. Residual toxicities (except alopecia, fatigue, and Grade 2 hypothyroidism) due to prior anti-tumor therapy (including immunotherapy, targeted therapy, chemotherapy or radiotherapy) or ≥ Grade 1 (CTCAE v5.0) clinically significant laboratory abnormality.
- 6. Uncontrolled or poorly controlled cardiac dysfunction, including congestive heart failure (CHF) ≥ Grade 2 (CTCAE v5.0 or New York Heart Association classification), history of myocardial infarction, unstable angina pectoris, ventricular tachycardia or torsades de pointes, or cardiac rhythm loss requiring treatment within 6 months prior to enrollment, for example, QTcF > 450 ms in men, QTcF > 470 ms in women, in presence of complete left bundle branch block or third-degree atrioventricular block. QTcF = QT/ (RR^0.33).
- 7. Pulmonary embolism or deep venous thrombosis (except for thrombosis caused by infusion port or PICC line) within 3 months prior to the first dose of study drug.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MRG003Administered intravenously | Drug | MRG003 |
| Cetuximab injectionAdministered intravenously | Drug | cetuximab/ methotrexate |
| Methotrexate InjectionAdministered intravenously | Drug | cetuximab/ methotrexate |
Primary outcome
Overall Survival (OS)
Time frame: Baseline to study completion (up to 24 months)
OS is defined as the duration from the start of treatment to death of any cause.
8 secondary outcomes
Progression Free Survival (PFS)
Time frame: Baseline to study completion (up to 24 months)
Objective Response Rate (ORR)
Time frame: Baseline to study completion (up to 24 months)
Disease Control Rate (DCR)
Time frame: Baseline to study completion (up to 24 months)
Duration of Response (DOR)
Time frame: Baseline to study completion (up to 24 months)
Treatment Related Adverse Events (TRAE)
Time frame: Baseline to 30 days after the last dose of study treatment
Adverse Events (AEs)
Time frame: Baseline to 30 days after the last dose of study treatment
Serious Adverse Events (SAEs)
Time frame: Baseline to 90 days after the last dose of study treatment
Quality of Life (QOL) scores
Time frame: Baseline to study completion (up to 24 months)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Squamous Cell Carcinoma of the Head and Neck
RecruitingPhase 1/2
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
RecruitingObservational study
Salivary IL-8 and Serum IL-6 as Biomarkers for Oral Potentially Malignant Disorders in Smokers and Never-Smokers
Oral Potentially Malignant Disorders, Oral Lichen Planus
RecruitingPhase 3
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
Head and Neck Squamous Cell Carcinoma, Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
Not yet recruitingPhase 2
Becotatug Vedotin Plus Pucotenlimab in Locally Advanced Head and Neck Squamous Cell Carcinoma With Suboptimal Response to Induction Immunochemotherapy
Squamous Cell Carcinoma of Head and Neck (SCCHN)
RecruitingPhase 1
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Metastatic Solid Tumor, Recurrent Solid Tumor
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Ye Guo, PhD principal investigator
Shanghai East Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing MRG003, Cetuximab injection and Methotrexate Injection in people with Squamous Cell Carcinoma of the Head and Neck, run by Lepu Biopharma Co., Ltd. at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 19 inclusion and 22 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 4 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Program Director (86-21-61637960, clinicaltrials@miracogen.com.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall Survival (OS) (time frame: Baseline to study completion (up to 24 months)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Sep 2026.